Hepcidin and Iron Status in Patients With Inflammatory Bowel Disease Undergoing Induction Therapy With Vedolizumab or Infliximab
Inflammatory Bowel Diseases · 01.08.2023 · 29 (8) · 1272-1284
DOI: 10.1093/ibd/izad010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 07.02.2023. Verfasst von Roberta Loveikyte und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden University, Leiden, the Netherlands. Hauptthemen laut MEDLINE: Anemia, Iron-Deficiency, Inflammatory Bowel Diseases, Iron Deficiencies. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Crohn's and Colitis and Cablon Medical.
Abstract (Originalsprache)
Background
Hepcidin, the systemic iron regulator, could be critical in differentiating iron deficiency (ID) from functional iron restriction in inflammatory bowel disease (IBD). We assessed hepcidin as a diagnostic ID marker and explored the relationship between hepcidin and its regulators in patients with IBD undergoing induction therapy with infliximab (IFX) or vedolizumab (VEDO).
Methods
Patients with active IBD receiving induction therapy with IFX or VEDO were included. Serum samples at baseline and after 6 weeks of induction therapy were analyzed for hepcidin, inflammation- and hypoxia-associated cytokines, and oxidative stress. Data were analyzed by stratifying based on the response at week 14. Results were compared with samples from age- and sex-matched healthy control subjects.
Results
Patients receiving induction therapy with IFX (n = 71) or VEDO (n = 51) and healthy control subjects (n = 50) were included. At baseline, hepcidin correlated positively with ferritin and negatively with soluble transferrin receptor/log ferritin index (P < .001). ID was prevalent in 96.7% of patients who had hepcidin levels below the median. Hepcidin accurately identified ID: the area under the curve (hepcidin) was 0.89 (95% confidence interval, 0.82-0.95; P < .001). In total, 75.4% of patients responded to induction therapy; inflammation, hepcidin, and ferritin decreased significantly, while transferrin increased during induction therapy. These changes were observed only in patients who responded to the therapy.
Conclusions
Hepcidin levels in IBD are primarily determined by ID, even in an inflammatory state. In addition, induction therapy can decrease hepcidin levels, which might lead to better bioavailability of iron supplements. Therefore, hepcidin is a potential diagnostic ID biomarker that could assist therapeutic decision making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden University, Leiden, the Netherlands.
- Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
- Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
ORCID-Profile: Roberta Loveikyte, Arno R Bourgonje
Förderung
- Crohn's and Colitis and Cablon Medical
Zitieren
APA
Loveikyte, R., Bourgonje, A. R., van der Reijden, J. J., Bulthuis, M. L. C., Hawinkels, L. J. A. C., Visschedijk, M. C., Festen, E. A. M., van Dullemen, H. M., Weersma, R. K., van Goor, H., van der Meulen-de Jong, A. E., & Dijkstra, G. (2023). Hepcidin and Iron Status in Patients With Inflammatory Bowel Disease Undergoing Induction Therapy With Vedolizumab or Infliximab. Inflammatory Bowel Diseases, 29(8), 1272-1284. https://doi.org/10.1093/ibd/izad010
Vancouver
Loveikyte R, Bourgonje AR, van der Reijden JJ, Bulthuis MLC, Hawinkels LJAC, Visschedijk MC, et al. Hepcidin and Iron Status in Patients With Inflammatory Bowel Disease Undergoing Induction Therapy With Vedolizumab or Infliximab. Inflammatory Bowel Diseases. 2023;29(8):1272-1284. doi:10.1093/ibd/izad010
BibTeX
@article{Loveikyte2023,
author = {Loveikyte, Roberta and Bourgonje, Arno R and van der Reijden, Johannes J and Bulthuis, Marian L C and Hawinkels, Lukas J A C and Visschedijk, Marijn C and Festen, Eleonora A M and van Dullemen, Hendrik M and Weersma, Rinse K and van Goor, Harry and van der Meulen-de Jong, Andrea E and Dijkstra, Gerard},
title = {Hepcidin and Iron Status in Patients With Inflammatory Bowel Disease Undergoing Induction Therapy With Vedolizumab or Infliximab},
journal = {Inflammatory Bowel Diseases},
year = {2023},
volume = {29},
number = {8},
pages = {1272--1284},
doi = {10.1093/ibd/izad010}
}
EUVIMED